Chemical Proteomics: Drug Targets, Drug Selectivity, MoA and Resistance
Conference Recording Apr 24, 2013
About the SpeakerDr. Guillaume Médard graduated from the Ecole Nationale Supérieure de Chimie de Montpellier in 2002. After an organic chemistry research masters on triazenes at Louis Pasteur University, Strasbourg, he moved across the Channel for a PhD at University College London. There, he worked on different strategies for the synthesis of 9,10-secosteroids. In 2007 he joined Argenta Discovery as a medicinal chemist where he contributed to kinase inhibitors drug discovery programmes in collaboration with Genentech. He joined Prof. Kuster at the Technische Universität München where he was appointed to lead the chemical proteomics efforts of the group in 2011. His current research focuses on the design and synthesis of chemical probes for the enrichment of sub-proteomes, the profiling of kinase inhibitors by kinobeads competitive assays combined with quantitative mass spectrometry, and the development of selective small molecule inhibitors for kinases missing such tools.
This presentation gives examples for how mass spectrometry based chemical proteomics can aid at various stages in the drug discovery process including the identification of new drug targets, the selectivity of kinase inhibitors, the elucidation of the mechanism of action of drugs targeting HSP90 and identify mechanisms of resistance against targeted kinase inhibitors.
Comments | 0 ADD COMMENT
Protein Discovered that Protects Against Fatty Liver
News Jan 18, 2017